Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Long-Term Debt Repayments (2022 - 2024)

Ensysce Biosciences (ENSC) has disclosed Long-Term Debt Repayments for 3 consecutive years, with $485190.0 as the latest value for Q1 2024.

  • On a quarterly basis, Long-Term Debt Repayments rose 16.81% to $485190.0 in Q1 2024 year-over-year; TTM through Dec 2024 was $485190.0, a 51.49% decrease, with the full-year FY2024 number at $485190.0, down 51.49% from a year prior.
  • Long-Term Debt Repayments was $485190.0 for Q1 2024 at Ensysce Biosciences, down from $584857.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $1.1 million in Q4 2022 to a low of $415351.0 in Q1 2023.
  • A 3-year average of $656987.5 and a median of $535023.5 in 2023 define the central range for Long-Term Debt Repayments.
  • Biggest YoY gain for Long-Term Debt Repayments was 16.81% in 2024; the steepest drop was 16.81% in 2024.
  • Ensysce Biosciences' Long-Term Debt Repayments stood at $1.1 million in 2022, then plummeted by 48.81% to $584857.0 in 2023, then dropped by 17.04% to $485190.0 in 2024.
  • Per Business Quant, the three most recent readings for ENSC's Long-Term Debt Repayments are $485190.0 (Q1 2024), $584857.0 (Q2 2023), and $415351.0 (Q1 2023).